You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for lutetium lu-177 vipivotide tetraxetan and what is the scope of patent protection?

Lutetium lu-177 vipivotide tetraxetan is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lutetium lu-177 vipivotide tetraxetan has ninety-one patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
International Patents:91
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 4
DailyMed Link:LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Generic Entry Date for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Novartis PharmaceuticalsPhase 2
Novartis PharmaceuticalsPhase 4
Prostate Cancer Clinical Trials ConsortiumPhase 2

See all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN clinical trials

Pharmacology for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

US Patents and Regulatory Information for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Country Patent Number Title Estimated Expiration
China 109053616 前列腺特异性膜抗原(PSMA)的标记的抑制剂及其用途 (Labeled inhibitors of prostate specific membrane antigen (PSMA), and use thereof) ⤷  Sign Up
European Patent Office 3388086 CONJUGUÉS COMPRENANT UN LIGAND DU PSMA ET UN LIEUR ET PROCÉDÉS POUR LEUR UTILISATION (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING) ⤷  Sign Up
Georgia, Republic of P20237496 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER ⤷  Sign Up
Japan 2010536790 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.